Banano Biotechnology Co., Ltd. (hereinafter referred to as “Banano”) was established in 2023 and is a high-tech enterprise centered on the research, development, and industrialization of high-throughput genetic testing technologies. The company has introduced internationally leading third-generation sequencing technology—nanopore sequencing—and has proactively deployed major third-generation sequencing platforms both domestically and internationally. To date, Banano has carried out systematic testing and product development on the one of the most advanced sequencing platform, thereby establishing an efficient, multi-platform nanopore sequencing technology and product development system that provides stable and reliable technical support for scientific research services and clinical translational applications.
Leveraging expert resources from both China and abroad, together with continuous technological accumulation, Banano has progressively built a multidisciplinary R&D team and formed a technology development system characterized by an international perspective and cross-disciplinary strengths. With third-generation nanopore sequencing as its core technological foundation, the company has independently developed an integrated sequencing-and-analysis instrument and a supporting bioinformatics analysis system, establishing a full-process technology chain encompassing sample data acquisition, real-time sequencing, result interpretation, and report generation. In the field of clinical medicine, Banano focuses on the detection of infectious diseases, screening of genetic and rare diseases, gut microbiome analysis, molecular oncology testing, and molecular testing related to assisted reproduction, continuously advancing the development and application of high-sensitivity molecular diagnostic technologies. In the agricultural sector, the company concentrates on the development and translation of testing technologies for genetic evaluation during non-invasive bovine embryo culture. In the environmental field, Banano emphasizes the application of microbial detection in soil improvement and ecological regulation, exploring practical pathways for the application of multi-omics technologies in environmental microbiome monitoring and assessment. The company is committed to delivering precise, reliable, and scalable testing and monitoring solutions across these domains, thereby supporting the high-quality development of precision medicine and related industries.
With respect to industrialization and quality management, Banano has established R&D bases and production laboratories in Chongqing and Wuhan, forming a relatively comprehensive system encompassing research and development, manufacturing, and quality management. The Chongqing laboratory has obtained Class I medical device manufacturing registration and ISO 13485 quality management system certification, providing standardized and systematic assurance for product development, manufacturing, and quality control. To date, the company has been granted 12 software copyrights, with an additional 5 currently under application, and has filed 5 patent applications, resulting in a systematic portfolio of independently owned intellectual property. In addition, Wuhan Banano Biotechnology Co., Ltd. has been recognized as a National High-Tech Enterprise in China, further strengthening the company’s technological capabilities and industrial foundation.
Figure 1: Patents and Soft Works
